|
53 Companies |
|
51 Products |
|
51 Products |
|
62 Mechanisms of Action |
|
0 Trials |
|
1105 News |
|
| «12...89101112131415161718...1920» |
- Enrollment open: PreColos: Feeding Bovine Colostrum to Preterm Infants (clinicaltrials.gov) - Mar 13, 2014
P=N/A, N=50, Recruiting, Sponsor: Arne Astrup
Not yet recruiting --> Recruiting
- New P2/3 trial: Effects of BCG on Immune Response (clinicaltrials.gov) - Mar 11, 2014
P2/3, N=20, Not yet recruiting, Sponsor: Radboud University
- Trial completion: Perinatal Handwashing Intervention in Bangladesh (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=400, Completed, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Not yet recruiting --> Recruiting Recruiting --> Completed
- New P4 trial: Effect of Different Strategies for Titrating a High MAP on Microcirculation (clinicaltrials.gov) - Mar 10, 2014
P4, N=20, Recruiting, Sponsor: Southeast University, China
- ||| Enrollment open: TailoredT: Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis (clinicaltrials.gov) - Mar 7, 2014
P=N/A, N=1200, Recruiting, Sponsor: MeMed Diagnostics Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial termination: HYSATESS-p: Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension (clinicaltrials.gov) - Mar 6, 2014
P3, N=21, Terminated, Sponsor: Hospital General de Ciudad Real
Not yet recruiting --> Recruiting Recruiting --> Terminated; Low recruitment rate
- Enrollment change: HYSATESS-p: Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension (clinicaltrials.gov) - Mar 6, 2014
P3, N=21, Terminated, Sponsor: Hospital General de Ciudad Real
Recruiting --> Terminated; Low recruitment rate N=42 --> 21
- ||| Trial completion: Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers (clinicaltrials.gov) - Mar 6, 2014
P1, N=56, Completed, Sponsor: Medicines for Malaria Venture
N=42 --> 21 Active, not recruiting --> Completed
- Clinical: Ninj1: The Role of Ninjurin-1 During Systemic Inflammation (clinicaltrials.gov) - Mar 4, 2014
P=N/A, N=18, Recruiting, Sponsor: Dr. Patrick Meybohm, M.D.
- | New P4 trial: CLASSIC: Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (clinicaltrials.gov) - Mar 3, 2014
P4, N=150, Not yet recruiting, Sponsor: Anders Perner
- Enrollment closed: ADSeS: Examination of ADMA Serum Level and DDAH II (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=120, Active, not recruiting, Sponsor: Universit
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial completion: Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock (clinicaltrials.gov) - Feb 25, 2014
P2, N=31, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- vancomycin / Generic mfg.
Enrollment open: The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)? (clinicaltrials.gov) - Feb 24, 2014
P=N/A, N=1500, Recruiting, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| NN1213 / Novo Nordisk
Trial completion: Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections (clinicaltrials.gov) - Feb 22, 2014
P1, N=208, Completed, Sponsor: John H. Stroger Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Infecir: Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Feb 22, 2014
P3, N=110, Completed, Sponsor: Hospital Clinic of Barcelona
Recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Alcohol Locks for the Prevention of Tunneled Catheter-related Infections (clinicaltrials.gov) - Feb 22, 2014
P2/3, N=440, Completed, Sponsor: Erasmus Medical Center
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| NN1213 / Novo Nordisk
Trial completion: Safety and Efficacy of Veronate (clinicaltrials.gov) - Feb 22, 2014
P3, N=2000, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: HETRASE: Unfractioned Heparin for Treatment of Sepsis (clinicaltrials.gov) - Feb 22, 2014
P3, N=319, Completed, Sponsor: Universidad de Antioquia
No longer recruiting --> Completed Recruiting --> Completed
- NN1213 / Novo Nordisk
Trial completion: A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation (clinicaltrials.gov) - Feb 22, 2014
P4, N=7, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed Terminated --> Completed
- | Arbelic (telavancin) / Cumberland
Trial completion: ASSURE: Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia (clinicaltrials.gov) - Feb 22, 2014
P2, N=60, Completed, Sponsor: Theravance, Inc.
Terminated --> Completed Recruiting --> Completed
- ||||||| fluconazole oral / Generic mfg.
Trial completion: The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis (clinicaltrials.gov) - Feb 22, 2014
P3, N=256, Completed, Sponsor: Pfizer
Recruiting --> Completed No longer recruiting --> Completed
- |||| NN1213 / Novo Nordisk
Trial completion: A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated) (clinicaltrials.gov) - Feb 22, 2014
P4, N=2000, Completed, Sponsor: Eli Lilly and Company
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| NN1213 / Novo Nordisk
Trial completion: Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis (clinicaltrials.gov) - Feb 22, 2014
P3, N=474, Completed, Sponsor: Eli Lilly and Company
No longer recruiting --> Completed No longer recruiting --> Completed
- Trial initiation date: Cholecalciferol Supplementation for Sepsis in the ICU (clinicaltrials.gov) - Feb 22, 2014
P3, N=30, Recruiting, Sponsor: Massachusetts General Hospital
No longer recruiting --> Completed Initiation date: Aug 2013 --> Jan 2014
- Enrollment open: Cholecalciferol Supplementation for Sepsis in the ICU (clinicaltrials.gov) - Feb 22, 2014
P3, N=30, Recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Aug 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- fludrocortisone / Generic mfg.
New P3 trial: Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock (clinicaltrials.gov) - Feb 20, 2014
P3, N=0, Withdrawn, Sponsor: Rennes University Hospital
- Enrollment open: Large Observational Study to UNderstand the Global Impact of Severe Acute Respiratory FailurE (clinicaltrials.gov) - Feb 17, 2014
P=N/A, N=1000, Recruiting, Sponsor: European Society of Intensive Care Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: ATHOS: Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study (clinicaltrials.gov) - Feb 17, 2014
P1, N=20, Completed, Sponsor: George Washington University
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| ceftaroline fosamil / Generic mfg.
Enrollment closed: Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia (clinicaltrials.gov) - Feb 9, 2014
P4, N=60, Active, not recruiting, Sponsor: Cerexa, Inc.
Recruiting --> Completed Recruiting --> Active, not recruiting
- New P1 trial: Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects (clinicaltrials.gov) - Feb 2, 2014
P1, N=15, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- Cubicin (daptomycin) / Merck (MSD)
Enrollment open: Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia (clinicaltrials.gov) - Feb 1, 2014
P2b, N=50, Recruiting, Sponsor: Singapore General Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Biomarker, Enrollment open: Neutrophil Gelatinase Associated Lipocalin (NGAL) in Urine: Can This Prove to be a Biomarker for Acute Kidney Injury in Patients With Sepsis? (clinicaltrials.gov) - Jan 31, 2014
P=N/A, N=40, Recruiting, Sponsor: Sygehus Lillebaelt
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Promune (agatolimod) / Pfizer
Trial termination, Gram negative: Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant (clinicaltrials.gov) - Jan 29, 2014
P1, N=20, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Suspended --> Terminated
- Promune (agatolimod) / Pfizer
Enrollment change, Gram negative: Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant (clinicaltrials.gov) - Jan 29, 2014
P1, N=20, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Suspended --> Terminated N=34 --> 20
- midazolam hydrochloride / Generic mfg.
New P1/2 trial: The Effect of Midazolam on Fluid Responsiveness in Septic Patients (clinicaltrials.gov) - Jan 29, 2014
P1/2, N=40, Completed, Sponsor: Southeast University, China
- ||| Enrollment open: Utility of Presepsin in Distinguishing Between Sepsis and SIRS (clinicaltrials.gov) - Jan 29, 2014
P=N/A, N=226, Recruiting, Sponsor: Mochida Pharmaceutical Company, Ltd.
N=34 --> 20 Not yet recruiting --> Recruiting
- midazolam hydrochloride / Generic mfg.
Trial completion: The Effect of Midazolam on Fluid Responsiveness in Septic Patients (clinicaltrials.gov) - Jan 29, 2014
P1/2, N=40, Completed, Sponsor: Southeast University, China
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- dexmedetomidine / Generic mfg.
Clinical: The Effects of Sedative on the Fluid Responsiveness in Critically Ill Patients (clinicaltrials.gov) - Jan 27, 2014
P1, N=100, Completed, Sponsor: Southeast University, China
Not yet recruiting --> Completed Recruiting --> Completed
- Trial completion, Adverse events: Medical Record Study on Adverse Events Requiring a Higher Level of Care in Flemish Hospitals (clinicaltrials.gov) - Jan 21, 2014
P=N/A, N=878, Completed, Sponsor: Hasselt University
Recruiting --> Completed Not yet recruiting --> Completed
- | Cubicin (daptomycin) / Merck (MSD)
Enrollment open, Monotherapy: Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia (clinicaltrials.gov) - Jan 20, 2014
P3, N=206, Recruiting, Sponsor: Miquel Pujol
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- tigecycline / Generic mfg., acetylcysteine solution / Generic mfg.
New P2/3 trial: Treatment of Hemodialysis Catheter-Related Bacteremia (clinicaltrials.gov) - Jan 16, 2014
P2/3, N=0, Not yet recruiting, Sponsor: University of California, San Diego
- Fragmin (dalteparin sodium) / Pfizer, Eisai
Enrollment closed: Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot (clinicaltrials.gov) - Jan 16, 2014
P2, N=76, Active, not recruiting, Sponsor: University of Manitoba
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ceftriaxone / Generic mfg., gentamicin sulfate / Generic mfg.
Enrollment closed: Infaseme: Infant Severe Sepsis and Bacterial Meningitis in Malawi (clinicaltrials.gov) - Jan 14, 2014
P4, N=238, Active, not recruiting, Sponsor: University of Malawi College of Medicine
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | gentamicin sulfate / Generic mfg., amoxicillin / Generic mfg.
Trial completion: SATT: Simplified Antibiotic Therapy for Sepsis in Young Infants (clinicaltrials.gov) - Jan 14, 2014
P3, N=2543, Completed, Sponsor: Aga Khan University
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment open: Pilot Study for the SQUEEZE Trial (clinicaltrials.gov) - Jan 5, 2014
P3, N=50, Recruiting, Sponsor: McMaster Children's Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- New P2/3 trial: Efficacy of Mw Vaccine in Treatment of Severe Sepsis (clinicaltrials.gov) - Dec 30, 2013
P2/3, N=50, Completed, Sponsor: Postgraduate Institute of Medical Education and Research
- ||| Biomarker, Trial completion: CURIOSITY: Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections (clinicaltrials.gov) - Dec 28, 2013
P=N/A, N=1001, Completed, Sponsor: MeMed Diagnostics Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Enrollment closed: TRISS: Transfusion-requirements in Septic Shock Trial (clinicaltrials.gov) - Dec 26, 2013
P3, N=1000, Active, not recruiting, Sponsor: Scandinavian Critical Care Trials Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- cefazolin / Generic mfg.
Enrollment open: An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates (clinicaltrials.gov) - Dec 21, 2013
P1, N=12, Recruiting, Sponsor: Phillip Brian Smith
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment change: ACROSS: Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis (clinicaltrials.gov) - Dec 20, 2013
P2a, N=51, Completed, Sponsor: Vanderbilt University
Not yet recruiting --> Recruiting N=40 --> 51